Clinical trials: Intravenous Injections
Multiple Sclerosis
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Background: Secondary-progressive multiple sclerosis (SP-MS) is the chronic phase of multiple sclerosis (MS). The majority of people who have relapsing-remitting MS eventually develop SP-MS.
- Trial name
- NCT01212094
- Testing
- Rituximab, normal saline
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Von Willebrand's Disease (VWD)
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Primary Objective: -To characterize the pharmacokinetics (PK) of BIVV001 after a single intravenous (IV) administration, as assessed by factor VIII (FVIII) activity determined by the one-stage activated partial thromboplastin…
- Trial name
- NCT04770935
- Testing
- efanesoctocog alfa (BIVV001)
- Where
- 4 sites in United States, France
- Volunteers
- 6 people
- Sponsor
- Bioverativ, a Sanofi company
Solid Tumor, Metastases to Soft Tissue
Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic Nivolumab
This phase II trial aims at investigating the role and effect of autologous CD1c (BDCA-1)+ myeloid dendritic cells in combination with intratumoral injection of the CTLA-4 blocking monoclonal antibody (mAb) ipilimumab and the…
- Trial name
- myDAvIpNi (NCT03707808)
- Testing
- intratumoral injection of autologous CD1c (BDCA-1)+ myDC, Intratumoral injection of ipilimumab and AS01b, IV nivolumab
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Universitair Ziekenhuis Brussel
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
To compare the safety and efficacy of antiretroviral therapy (zidovudine plus either didanosine or dideoxycytidine) versus antiretroviral therapy plus intravenous cytarabine (Ara-C) versus antiretroviral therapy plus intrathecal…
- Trial name
- NCT00001048
- Testing
- Filgrastim, Cytarabine, Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Burns
Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients
The primary objective of this study of Caldolor administered to hospitalized adult and pediatric burn patients is to determine the efficacy of Caldolor on reducing fever when compared to placebo when administered every 6 hours…
- Trial name
- NCT00606489
- Testing
- Caldolor
- Where
- 5 sites in United States, India
- Volunteers
- 61 people
- Sponsor
- Cumberland Pharmaceuticals
Blood-Brain Barrier, Bacterial Meningitis
Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis
Multiple preclinical and clinical studies, including the investigators' published work and the ongoing SOLUTION series, have consistently demonstrated that intracalvariosseous (ICO) injection can markedly increase drug exposure…
- Trial name
- FLAME (NCT07495150)
- Testing
- Intracalvariosseous injection vancomycin/tigecycline/polymyxin B, Intravenous injection vancomycin/tigecycline/polymyxin B, Conventional treatment
- Where
- 6 sites in China
- Volunteers
- 86 people
- Sponsor
- yilong Wang
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV…
- Trial name
- NCT02449291
- Testing
- APD421
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 568 people
- Sponsor
- Acacia Pharma Ltd
Gaucher Disease Type I
A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
This is a prospective single-center, open, single-arm, single-dose intravenous infusion study to evaluate the safety and initial efficacy, pharmacodynamic characteristics, immunogenicity, biodistribution, and viral shedding of…
- Trial name
- LY-M001 (NCT06162338)
- Testing
- LY-M001 Injection
- Where
- China
- Volunteers
- 3 people
- Sponsor
- He Huang
Orthopox Virus Infection
Tecovirimat Intravenous Treatment for Orthopox Virus Exposure
To provide a therapeutic option for patients not able to take the oral formulation of TPOXX (e.g., cannot swallow, vomiting) and who have confirmed or suspected (based on clinical signs and symptoms with known exposure while…
- Trial name
- TPOXX IV (NCT05380752)
- Testing
- TPOXX IV (Tecovirimat Injection, 10 mg/mL)
- Sponsor
- U.S. Army Medical Research and Development Command
Crohn Disease, Resection Margins
Cellvizio to Evaluate Margins in Crohn's Ileal Disease
Crohn disease is an inflammatory bowel disease. A surgical procedure is required in about 80% of cases. Surgery doesn't cure from Crohn's disease but the type of surgery remains important as there are several intraoperative risk…
- Conditions
- Crohn Disease, Resection Margins, Recurrence
- Trial name
- CELLVICROHN (NCT05805020)
- Testing
- cellvizio
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Healthy
A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein
A study in healthy man to investigate the absolute bioavailability of 100mg BI 765080, once administered as subcutaneous (SC) injection and once administered as intravenous infusion.
- Trial name
- NCT05075772
- Testing
- BI 765080
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Intravenous Drug Usage
Correlates and Consequences of Increased Immune Activation in Injection Drug Users
The goal of this study is to learn how injection drug use may affect the immune system.
- Trial name
- NCT01831284
- Testing
- Sigmoidoscopy with biopsy
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Ischemic Stroke, Acute
Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice
Acute ischemic stroke is one of the main diseases leading to high risk of disability and morbidity worldwide. Since intravenous thrombolysis(IVT) can effectively improve the long-term functional prognosis of acute ischemic…
- Trial name
- NCT06018181
- Testing
- Shuxuetong Injection
- Where
- 78 sites in China
- Volunteers
- 2,408 people
- Sponsor
- Dongzhimen Hospital, Beijing
Active Rheumatoid Arthritis
Pulse Steroid Injection in Refractory Rheumatoid Arthritis
Remission or low disease activity in active rheumatoid arthritis
- Trial name
- NCT06456489
- Testing
- Solumedrol
- Where
- Egypt
- Volunteers
- 268 people
- Sponsor
- Sohag University
Pneumonia, Myocardial Injury
Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.
The goal of this PHASE III clinical trial is to evaluate efficacy and safety of intravenous TAD® 600 mg/4 mL solution for injection in preventing myocardial injury in patients with pneumonia.
- Trial name
- NCT06296212
- Testing
- TAD® 600 mg/4 mL powder and solvent for solution for injection, Saline solution 0.9% of sodium chloride
- Where
- 7 sites in Italy
- Volunteers
- 178 people
- Sponsor
- Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica
Pompe Disease Infantile-Onset
Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug
This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease.
- Trial name
- NCT05793307
- Testing
- GC301
- Where
- 5 sites in China
- Volunteers
- 16 people
- Sponsor
- GeneCradle Inc
Dose Response Relationship, Drug
Infiltration Effect on SUV
A widely used semi-quantitative parameter to assess tumor status is the standardized uptake value (SUV). SUV estimation accuracy can be impacted by many variables.
- Trial name
- NCT03320564
- Testing
- F-18 FDG PET
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Diabetes Complications, Diabetes Mellitus
The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes
The goal of this pilot study is to obtain preliminary data on the magnitude of the treatment effect of IVIG on the neuropathic pain and neuropathy severity associated with treatment induced neuropathy (TIND).
- Conditions
- Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
- Trial name
- NCT02915263
- Testing
- IGIV-C, 0.9% Sodium Chloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Beth Israel Deaconess Medical Center
Pulmonary Hypertension
Safety of SonoVue on Pulmonary Hemodynamics
This is an intra-subject crossover comparative safety study to evaluate the effect of intravenous (IV) bolus injection of SonoVue on pulmonary hemodynamics.
- Trial name
- NCT01306292
- Testing
- SonoVue
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Bracco Diagnostics, Inc
Cardiovascular Diseases, Atherosclerosis
Clinical Transfer of a Vulnerable Atherosclerotic Plaque Tracer : 99mTc-cAbVCAM1-5 (ATHENA)
Clinical Transfer of a Tracer of the Vulnerable Atheroma Plate: 99mTc-cAbVCAM1-5. (ATHENA). This is a phase I/IIa, prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.
- Trial name
- ATHENA (NCT04483167)
- Testing
- 99mTccAbVCAM1-5 injection
- Where
- France
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble